Novartis, Mylan Spar Over Breast Cancer Treatment
Drug makers Novartis Pharmaceuticals and Mylan Pharmaceuticals will meet in court over the patents for breast cancer treatment Femara, after an Abbreviated New Drug Application prompted Novartis to slap the generics...To view the full article, register now.
Already a subscriber? Click here to view full article